As an accomplished senior executive with over two decades of experience in the biopharma industry, I have played a pivotal role in driving innovation and delivering strategic success. I bring a proven track record in scientific leadership, operational management, and technology development, having played a lead role in pioneering a novel class of TCR based therapeutics and contributed to the growth of Immunocore from a start-up to a globally recognised biotech leader with the commercialisation of its first approved drug in 2022.In my current role as Chief Technology Officer (CTO), I lead Immunocore’s drug discovery pipeline across oncology, infectious, and autoimmune diseases, managing all aspects from target validation to preclinical development. In addition, I oversee the development of Immunocore’s ImmTAX platform, focussing on streamlining processes and incorporating new technologies such as machine learning to bring the next generation of ImmTAX molecules and accelerate drug development.In addition to my scientific and technical leadership, as Immunocore’s UK site head, I am passionate about fostering collaboration and innovation within the scientific community. I have built strong relationships with academic institutions, biotech organisations, and industry bodies, positioning Immunocore as a key player in the UK's biotech landscape. This collaborative approach also informs my role as a Non-Executive Director at Advanced Oxford, I contribute to shaping the future of Oxford's innovation ecosystem, advocating for policies that enhance growth in the region.I am eager to leverage my experience in science, technology, and leadership to provide strategic guidance to organisations that prioritise innovation and growth. My particular interest lies in contributing to boards of companies at the intersection of biotechnology, healthcare, and technology, where I can help drive sustainable progress.